Ad-hoc | 16 March 2004 10:39

STRATEC Biomedical Systems AG: Preliminary Key Figures for FY 2003

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– STRATEC Biomedical Systems AG: Preliminary Key Figures for FY 2003 STRATEC Biomedical Systems AG excels in FY 2003 Birkenfeld, March 16, 2004 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard, announces the preliminary FY 2003 results, pursuant to Section 15 of the German Securities Trading Law (WpHG). With the Company’s very successful performance in 2003 STRATEC Biomedical Systems AG surpassed its forecast in sales and earnings per share. The preliminary FY 2003 key figures according to IFRS (International Financial Reporting Standards) are as follows: Key figures in EUR 000s 2003 2002 Change Sales 31,662 26,696 + 18.6% Overall Performance 32,807 28,120 + 16.7% EBITDA 3,987 2,831 + 40.8% EBIT 3,039 1,996 + 52.3% EBT 2,771 1,792 + 54.6% Annual net income 1,684 1,111 + 51.6% Earnings per share (EUR) 0.511 0.344 + 48.6% Earnings per share according to German Commercial Law were EUR 0.589 (previous year: EUR 0.376). At the end of FY 2003 STRATEC Biomedical Systems AG had 154 employees (previous year: 131). end of ad-hoc-announcement (c)DGAP 16.03.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: At the press conference on financial statements to be held in Stuttgart, Germany on April 6, 2004 STRATEC’s FY 2003 final results will be commented and an outlook on the Company’s future strategy will be given. Following the termination of the press conference the FY 2003 annual report of STRATEC Biomedical Systems AG will be available on the Company’s web site. The distribution of the annual reports by mail has been scheduled for April 8, 2004. This year’s Annual Shareholders’ Meeting will be held in Pforzheim, Germany on May 14, 2004. About STRATEC Biomedical Systems AG: STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems together with their own reagents to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. STRATEC is a publicly listed stock corporation. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and on other exchanges. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Tel: +49 7082 7916-43 Fax: +49 7082 7916-999 eMail: ir@stratec-biomedical.de ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart; Freiverkehr in Berlin-Bremen, Düsseldorf und München 161039 Mär 04